設計されたナノボディによって安定したβ2-アドレノ受容体のアドレナリン活性化構造
Aaron M Ring1,2, Aashish Manglik1, Andrew C Kruse1
1Department of Molecular and Cellular Physiology, Stanford University, Stanford, CA 94305, USA.
Nature
|September 24, 2013
まとめ
研究者は,アドレナリンに結合するβ2アドレノ受容体 (β2AR) の活性状態を捉えました. この突破は,リガンドの相性が異なるにもかかわらず,Gタンパク質結合受容体 (GPCRs) の保存された活性化メカニズムを明らかにしています.
科学分野:
- バイオケミストリーと構造生物学
- 分子薬理学 分子薬理学
- 膜タンパク質の構造と機能
背景:
- Gタンパク質結合受容体 (GPCR) は,ヒトの生理学にとって不可欠ですが,その活性化メカニズムは十分に理解されていません.
- 低親和性神経伝達物質に結合する活性状態のGPCRを捕獲することは,重要な課題でした.
- 以前の構造的研究は,高親和性リガンドや,ミュータゲネシスによる受容体安定化に依存していた.
研究 の 目的:
- ネイティブアゴニストによるGPCR活性化の構造的基礎を決定する.
- ベータ-2アドレノ受容体 (β2AR) がその内生性アゴニストであるアドレナリンと結合している活性状態を視覚化するために.
- 異なるGPCRアゴニストの間で保存されたリガンド認識と活性化モードを調査する.
主な方法:
- 誘導進化は,β2ARの活性状態を安定させるためのカメリドの抗体断片を設計するために使用されました.
- 活性化されたβ2AR.の高解像度構造を取得するために,X線結晶学を用いた.
- 3つの異なるアゴニストに結合するβ2ARの構造が決定されました:BI167107,ヒドロキシベンジルイソプロテレノール,アドレナリン.
主要な成果:
- 3つのアゴニストに結合した活性状態のヒトβ2ARの結晶構造を,100 nM~80 pMの親和度で得られた.
- アゴニストの多様な化学構造と相性にもかかわらず,リガンド認識と活性化モードが保存されていることが観察されました.
- アドレナリンに結合したβ2AR構造は,細胞外ループ3とトランスメブランヘリックス6の特定の再配置を示した.
- 2つの保存されたチロシン間の水媒介水素結合は,活性GPCR状態の潜在的な安定剤として特定されました.
結論:
- エンジニアリングされた抗体断片は,活性状態のGPCRsをネイティブリガンドで安定させ,構造研究を成功させることができます.
- β2ARは,アドレナリンのような低親和性の内生アゴニストでも,保存された活性化メカニズムを示しています.
- β2AR活性化に関する構造的洞察は,関連するGタンパク質結合受容体と薬物開発を理解するための基礎を提供します.
関連する概念動画
Adrenergic Neurons: Neurotransmission
5.4K
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which...
Synthesis: Catecholamine synthesis requires tyrosine, which...
5.4K
Adrenergic Receptors (Adrenoceptors): Classification
4.9K
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
4.9K
Adrenergic Receptors: ɑ Subtype
2.7K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.7K
Adrenergic Receptors: β Subtype
3.8K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.8K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.9K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.9K
Adrenergic Agonists: Therapeutic Uses
2.0K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.0K


